In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform.
Agent-based model
Human monoclonal antibodies
In silico trials
SARS-CoV-2
Vaccines
Journal
BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194
Informations de publication
Date de publication:
14 Dec 2020
14 Dec 2020
Historique:
received:
29
10
2020
accepted:
09
11
2020
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. We present an in silico platform that showed to be in very good agreement with the latest literature in predicting SARS-CoV-2 dynamics and related immune system host response. Moreover, it has been used to predict the outcome of one of the latest suggested approach to design an effective vaccine, based on monoclonal antibody. Universal Immune System Simulator (UISS) in silico platform is potentially ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2. In silico trials are showing to be powerful weapons in predicting immune responses of potential candidate vaccines. Here, UISS has been extended to be used as an in silico trial platform to speed-up and drive the discovery pipeline of vaccine against SARS-CoV-2.
Sections du résumé
BACKGROUND
BACKGROUND
SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects.
RESULTS
RESULTS
We present an in silico platform that showed to be in very good agreement with the latest literature in predicting SARS-CoV-2 dynamics and related immune system host response. Moreover, it has been used to predict the outcome of one of the latest suggested approach to design an effective vaccine, based on monoclonal antibody. Universal Immune System Simulator (UISS) in silico platform is potentially ready to be used as an in silico trial platform to predict the outcome of vaccination strategy against SARS-CoV-2.
CONCLUSIONS
CONCLUSIONS
In silico trials are showing to be powerful weapons in predicting immune responses of potential candidate vaccines. Here, UISS has been extended to be used as an in silico trial platform to speed-up and drive the discovery pipeline of vaccine against SARS-CoV-2.
Identifiants
pubmed: 33308153
doi: 10.1186/s12859-020-03872-0
pii: 10.1186/s12859-020-03872-0
pmc: PMC7733700
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
527Références
Front Immunol. 2019 Jan 21;9:3176
pubmed: 30719026
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
Bioinformatics. 2008 Aug 1;24(15):1715-21
pubmed: 18556669
Viruses. 2020 Feb 22;12(2):
pubmed: 32098422
Curr Cardiol Rep. 2020 Jun 11;22(7):52
pubmed: 32529517
Sci Rep. 2018 Feb 6;8(1):2465
pubmed: 29410461
DNA Cell Biol. 2007 Oct;26(10):721-6
pubmed: 17665998
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nat Med. 2004 Dec;10(12 Suppl):S88-97
pubmed: 15577937
Brief Bioinform. 2019 Sep 27;20(5):1699-1708
pubmed: 29868882
EBioMedicine. 2020 May;55:102743
pubmed: 32249203
Cancer Res. 2010 Oct 15;70(20):7755-63
pubmed: 20924100
NPJ Vaccines. 2020 Mar 6;5:18
pubmed: 32194995
Blood. 2010 Jun 3;115(22):4412-20
pubmed: 20308597
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
PLoS One. 2011;6(10):e26523
pubmed: 22028894
Expert Rev Mol Diagn. 2020 May;20(5):453-454
pubmed: 32297805
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Methods. 2020 Jan 25;:
pubmed: 31991193
J Theor Biol. 2010 Apr 21;263(4):530-43
pubmed: 20085772
CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):615-29
pubmed: 26783498
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
BMC Bioinformatics. 2019 Dec 10;20(Suppl 6):504
pubmed: 31822272
Proc Natl Acad Sci U S A. 2002 May 14;99 Suppl 3:7280-7
pubmed: 12011407
Vaccines (Basel). 2020 Mar 29;8(2):
pubmed: 32235387
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
Cell Stress. 2020 Mar 02;4(4):66-75
pubmed: 32292881
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
BMC Bioinformatics. 2017 Dec 28;18(Suppl 16):544
pubmed: 29297294
Cells. 2020 Mar 01;9(3):
pubmed: 32121606
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32751841
Ann Clin Microbiol Antimicrob. 2020 Sep 2;19(1):40
pubmed: 32878641
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Bioinformatics. 2015 Aug 1;31(15):2514-22
pubmed: 25810433
J Med Virol. 2020 Apr;92(4):418-423
pubmed: 31967327
IEEE/ACM Trans Comput Biol Bioinform. 2018 Sep-Oct;15(5):1492-1499
pubmed: 28767374
Bioinformatics. 2016 Sep 1;32(17):2672-80
pubmed: 27162187
Phys Life Rev. 2016 Jul;17:112-3
pubmed: 27185314
PLoS Pathog. 2013 Aug;9(8):e1003565
pubmed: 23966862
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Brief Bioinform. 2018 Dec 27;:
pubmed: 30590430
J Clin Med. 2020 Feb 26;9(3):
pubmed: 32110875
BMC Bioinformatics. 2010 Oct 15;11 Suppl 7:S13
pubmed: 21106120
Int J Mol Med. 2020 Sep;46(3):957-964
pubmed: 32705153
Cancers (Basel). 2020 Aug 10;12(8):
pubmed: 32785162
Clin Microbiol Infect. 2020 Jul;26(7):954-956
pubmed: 32229288
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Int J Mol Sci. 2020 Apr 10;21(7):
pubmed: 32290293
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Emerg Infect Dis. 2004 Feb;10(2):210-6
pubmed: 15030685
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508